For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

Scientists in Argentina have made history by creating the world's first genetically modified horses, designed to be faster ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...